Methylenedioxybenzylamphetamine
Methylenedioxybenzylamphetamine, abbreviated MDBZ, and systematically named 3,4-methylenedioxy-N-benzylamphetamine, is a psychedelic drug. It is the N-benzyl derivative of 3,4-methylenedioxyamphetamine (MDA). MDBZ was first synthesized by Alexander Shulgin. In his book PiHKAL (Phenethylamines i Have Known And Loved), the minimum dosage is listed as 150 mg, and the duration unknown. Very few data exist about the pharmacological properties, metabolism, and toxicity of MDBZ.
Names | |
---|---|
Preferred IUPAC name
1-(2H-1,3-Benzodioxol-5-yl)-N-benzylpropan-2-amine | |
Identifiers | |
3D model (JSmol) |
|
ChemSpider | |
PubChem CID |
|
UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
Properties | |
C17H19NO2 | |
Molar mass | 269.343 g/mol |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
Infobox references |
In an episode of the British spoof documentary TV show Brass Eye, David Amess MP was fooled into recording a warning against a fictitious new drug called "cake". When asked a parliamentary question about it, the Home Office incorrectly assumed Amess was referring to MDBZ.[1]
Legality
United Kingdom
MDBZ is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act.[2]
See also
References
- "House of Commons Hansard Written Answers for 23 July 1996 (pt 10)". Parliamentary Debates (Hansard). 23 July 1996.
- "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Retrieved 12 March 2014.